Jun 4, 2008 - Javelin Pharmaceuticals, Inc. (Amex: JAV), a leading developer of specialty prescription medications for pain management was today granted a commercially important patent in the European Union that extends patent protection for Javelin's PMI-150 (intranasal ketamine) drug candidate into 2023. European Patent No. 1 562 566 B1, entitled: "Analgesic Compositions Comprising NMDA Receptor Antagonists and Benzalkonium Chloride," will cover the major EU market countries (G5) as well as an additional 20 Member States of the European Patent Convention. This new patent is the European counterpart to Javelin's U.S. Patent No. 7,273,889 that issued in September, 2007.
"The extension of Javelin's intranasal ketamine patent portfolio in Europe is an important milestone for our company," said Martin Driscoll, Javelin's Chief Executive Officer. "The issuance of this European patent extends the term of commercial exclusivity for Javelin's intranasal ketamine by almost a decade. This extension in the market exclusivity for intranasal ketamine should significantly enhance the potential value of the PMI-150 franchise and further bolster our global partnership discussions."
The details can be read here.
No comments:
Post a Comment